Chanazine 2% Injection for use in cattle, horses, dogs and cats 25ml

Chanazine 2% Injection for use in cattle, horses, dogs and cats 25ml.

Uses
Chanazine 2% is a sedative with analgesic and muscle relaxant properties for use in cattle, horses, dogs and cats. Chanazine 2% can be used in many cases where sedation is required, including:
1Handling fractious animals e.g. for transportation.
2Medical examinations e.g. X-ray examination, removal of bandages, examination of the penis and oral cavity.
3Premedication for minor superficial operations and local or regional anaesthesia.
4Elimination of defaecation when examining and treating the vagina, uterus and hindquarters.

Dosage and administration
Cattle
Chanazine 2% is given by intramuscular injection. The dose-rate is 0.05-0.3 mg/kg bodyweight (0.25-1.5 ml/100 kg), according to the degree of sedation required. Very fractious animals may require the higher dose rates not exceeding 0.3 mg/kg (Dose rate 4)

Dose 1:
Sedation with slight decrease in muscle tone.
Dose 2:
Sedation, marked decrease in muscle tone and some analgesia. The animal usually remains standing.
Dose 3:
Deep sedation, further decrease in muscle tone and a useful degree of analgesia. The animal lies down.
Dose 4:
Very deep sedation, a profound decrease in muscle tone and a useful degree of analgesia. The animal lies down.
Animals should not be disturbed until Chanazine has taken its full effect. Onset of effect is usually seen within 15 minutes and effects persist for approximately 45 - 60 minutes depending on the dosage rate used. Induction and recovery are smooth. Local anaesthetics should be used in combination with Chanazine where major surgical treatment is carried out.
Horses
Chanazine 2% is given by slow intravenous injection. Dosage depends upon the degree of sedation required and the response of the animal, and is 0.6 - 1 mg/kg (3–5 ml/100 kg) bodyweight. Nervous or excitable horses may require higher doses. Older horses and those having undergone severe physical exertion before treatment should receive the lowest dose rate. The horse does not usually become recumbent after administration and light to deep sedation with variable degree of analgesia is obtained. Effects are usually seen within 5 minutes and persist for approximately 20 minutes. Chanazine 2% may be employed in the horse as a premedication to barbiturate anaesthesia or in combination with regional or local anaesthesia.
Dogs
Chanazine 2% is administered intramuscularly at dose rates of 1–3 mg/kg (0.05–0.15 ml/kg bodyweight). For painful procedures it may be used in combination with a local anaesthetic.
Premedication with atropine may be desirable in some cases. Chanazine 2% is synergistic with the barbiturates and reduces the dosage of the latter by approximately one half.
Cats
Chanazine 2% is administered intramuscularly at a dose rate of 3 mg/kg (0.15 ml/kg) bodyweight. Premedication with atropine may occasionally be desirable.

Contra-indications, warnings, etc
Do not administer by the intra-carotid route.
Careful consideration should be given before administering to animals exposed to stress conditions such as extreme heat, cold, high altitude or fatigue.
Following use of Chanazine 2% in cattle profuse salivation, bloat and polyuria may occur. Tympany should be avoided in recumbent cattle by maintaining the animal in sternal recumbency. Provision should also be made for facilitating dependent drainage from the mouth to avoid inhalation asphyxia.
Side Effects such as bradycardia, cardiac arrhythmia and polyuria may occur in the horse. Following intravenous administration to horses, a transient rise followed by a fall in blood pressure usually occurs.
Profound cardiovascular effects or exacerbated side effects specified above may result from overdosage. Cattle are 10 times more sensitive than horses. Do not repeat the dose in the event of unsatisfactory response. Repeat on the following day with recalculated dosage.
Vomiting is commonly observed in dogs and cats following use of the preparation.
Chanazine 2% should not be administered in the later stages of pregnancy because of the risk of inducing premature parturition. As the safety of xylazine use during organogenesis has not been fully demonstrated by current methods it should be used with caution during the first month of pregnancy.
Not to be used where pulmonary disease or gastro-intestinal obstruction are suspected.

Withdrawal Period
Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 14 days from the last treatment. Not for use in animals from which milk is produced for human consumption. Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Operator warnings
Xylazine is an alpha adrenoceptor agonist acting primarily on alpha-2 receptors. Precautions should be taken to avoid accidental injection /self injection.
Horses sedated with Xylazine usually remain standing and may still kick with accuracy.
1. In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet to the doctor but DO NOT DRIVE as sedation and changes in blood pressure may occur.
2. Avoid skin, eye or mucosal contact.
3. Immediately after exposure, wash the exposed skin with large amounts of fresh water.
4. Remove contaminated clothes that are in direct contact with skin.
5. In the case of accidental contact of the product with eyes, rinse with large amounts of fresh water. If symptoms occur, seek the advice of a doctor.
6. If pregnant women handle the product, special caution should be observed not to self inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.
7. Advice to Doctors: Xylazine is an alpha2-adrenoreceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, brachycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.

Environmental warnings
Dispose of any unused product or containers in accordance with guidance from your local waste regulation authority.

General precautions
For animal treatment only. Keep out of the reach of children.

Pharmaceutical precautions
Do not store above 25°C. Following withdrawal of the first dose, use the product within 28 days. For the ease of calculation of dates, the date of broaching of the product must be written in the box provided on the bottle label.

Legal category
Legal category: POM-V

Packaging quantities
Vials of 25 ml.